🇺🇸 FDA
Patent

US 8765813

Use of treprostinil to treat and prevent ischemic lesions

granted A61KA61K31/191A61K31/201

Quick answer

US patent 8765813 (Use of treprostinil to treat and prevent ischemic lesions) held by United Therapeutics Corporation expires Mon Jun 26 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
United Therapeutics Corporation
Grant date
Tue Jul 01 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 26 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
41
CPC classes
A61K, A61K31/191, A61K31/201, A61K31/557, A61P